Comparable stake leader
Fresenius Medical Care AG
SEC ownership of Humacyte, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001818382.
Disclosed value leader
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- HUMA, HUMAW on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Fresenius Medical Care AG
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Fresenius Medical Care AG
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001818382
- Issuer location
- Durham, NC
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Humacyte, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fresenius Medical Care AG
Disclosed value leader
FRESENIUS MEDICAL CARE HO...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 9.5%
13D/G row: Fresenius Medical Care AG
Showing 1-8 of 50 holder rows.
Quick read
Fresenius Medical Care AG leads the comparable SEC ownership view at 9.5%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fresenius Medical Care AG's linked filing trail.
Comparable ownership
Top 5
Fresenius Medical Care AG
9.5%
FRESENIUS MEDICAL CARE HOLDINGS I...
4.9%
DAVIDSON KEMPNER CAPITAL MANAGEME...
4.7%
BlackRock, Inc.
1.5%
VANGUARD CAPITAL MANAGEMENT LLC
3.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fresenius Medical Care AG |
13D/G
Fresenius Medical Care Holdings, Inc.
|
9.5%
|
—
18,312,735 shares
|
$0 | 01 Jan 2026 |
| FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ |
3/4/5
13D/G
Former 10% Shareholder · Fresenius Medical Care Holdings, Inc.
|
4.9%
from 13D/G
|
$21,792,154
18,312,735 shares
|
— | 26 Aug 2021 |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP |
13D/G
13F
Company
|
4.7%
|
$16,367,453
12,787,073 shares
|
$0 | 12 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
1.5%
from 13D/G
|
$3,777,079
4,839,929 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.7%
|
$7,883,990
10,107,679 shares
|
— | 30 Jun 2026 |
| ANTIPODES PARTNERS Ltd |
13F
Company
|
3.7%
|
$7,884,886
10,103,647 shares
|
— | 30 Jun 2026 |
| Alyeska Investment Group, L.P. |
13F
Company
|
2.2%
|
$4,700,291
6,022,925 shares
|
— | 30 Jun 2026 |
| GREAT POINT PARTNERS LLC |
13F
Company
|
1.4%
|
$2,926,500
3,750,000 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$2,296.
Buys
$84,589
Insiders: 3
Sells
$82,294
Insiders: 2
Net
+$2,296
Shares: +16,044
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 107,818
Shares: 91,774
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 40,000 | 0 | $24,750 | $0 | +$24,750 |
| 3-6 | 67,818 | 91,774 | $59,839 | $82,294 | -$22,454 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to Humacyte, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
Net 12M change
+$2,296
Latest report
20 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ | Former 10% Shareholder | $21,792,154 | Mixed | 26 Aug 2021 | ||
| Ayabudge LLC | 10%+ Owner | $9,747,457 | Mixed | 17 Aug 2023 | ||
| Brady W. Dougan | Director | $3,382,780 | Mixed | 11 Jun 2026 | ||
| Laura E. Niklason | President, CEO and Director, Director | $3,382,780 | Mixed | 11 Jun 2026 | ||
| Gordon M. Binder | Director | $1,413,300 | Filing P/S | 15 May 2024 | ||
| Dale A. Sander | CFO and Chief Corp. Dev. Off | $264,241 | -$41,147 | -13% | Mixed | 18 May 2026 |
| Shamik J. Parikh | Chief Medical Officer | $244,541 | -$41,147 | -14% | Filing P/S | 18 May 2026 |
| Kathleen Sebelius | Director | $130,262 | +$50,000 | +62% | Filing P/S | 11 Jun 2026 |
| William Edward Tente | Chief Regulatory Officer | $62,498 | Mixed | 26 Aug 2021 | ||
| Constantino Michael T. | Director | $39,313 | +$9,840 | +33% | Filing P/S | 11 Jun 2026 |
| William John Scheessele | Chief Commercial Officer | $33,908 | Filing P/S | 14 Apr 2025 | ||
| Keith Anthony Jones | Director | $27,719 | +$24,750 | +834% | Filing P/S | 20 Aug 2026 |
| Charles Bruce Green | Director | $10,836 | Filing P/S | 11 Jun 2026 | ||
| Jeffrey Harold Lawson | Chief Surgical Officer, Director | $9,374 | Mixed | 26 Aug 2021 | ||
| Heather Ledbetter Prichard | Chief Operating Officer | $0 | Mixed | 21 Jan 2025 | ||
| Richards Windham Bannister | Director | Mixed | 11 Jun 2026 | |||
| John Philip Bamforth | Director | Mixed | 11 Jun 2026 | |||
| Rajiv Shukla | Director | Mixed | 15 Jun 2023 | |||
| Emery N. Brown | Director | Mixed | 11 Jun 2026 | |||
| Todd Pope | Director | Mixed | 12 Jun 2025 |
Recent insider transactions for Humacyte, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Keith Anthony Jones | HUMA | Common Stock | Purchase | 33.3% | $6,930 | $0.6930 | 10,000 | 40,000 | 20 Aug 2026 | Direct |
| Keith Anthony Jones | HUMA | Common Stock | Purchase | $17,820 | $0.5940 | 30,000 | 30,000 | 17 Aug 2026 | Direct | |
| Richards Windham Bannister | HUMA | Stock Options (right to buy) | Award | 80,000 | 80,000 | 11 Jun 2026 | Direct | |||
| Constantino Michael T. | HUMA | Stock Options (right to buy) | Award | 80,000 | 80,000 | 11 Jun 2026 | Direct | |||
| Max N. Wallace | HUMA | Stock Options (right to buy) | Award | 80,000 | 80,000 | 11 Jun 2026 | Direct | |||
| Laura E. Niklason | HUMA | Stock Options (right to buy) | Award | 80,000 | 80,000 | 11 Jun 2026 | By spouse | |||
| Kathleen Sebelius | HUMA | Stock Options (right to buy) | Award | 80,000 | 80,000 | 11 Jun 2026 | Direct | |||
| Keith Anthony Jones | HUMA | Stock Options (right to buy) | Award | 80,000 | 80,000 | 11 Jun 2026 | Direct | |||
| Charles Bruce Green | HUMA | Stock Options (right to buy) | Award | 80,000 | 80,000 | 11 Jun 2026 | Direct | |||
| Diane Seimetz | HUMA | Stock Options (right to buy) | Award | 80,000 | 80,000 | 11 Jun 2026 | Direct | |||
| John Philip Bamforth | HUMA | Stock Options (right to buy) | Award | 80,000 | 80,000 | 11 Jun 2026 | Direct | |||
| Emery N. Brown | HUMA | Stock Options (right to buy) | Award | 80,000 | 80,000 | 11 Jun 2026 | Direct | |||
| Brady W. Dougan | HUMA | Stock Options (right to buy) | Award | 0 | 0 | 11 Jun 2026 | Direct | |||
| Kathleen Sebelius | HUMA | Common Stock | Purchase | 62.3% | $50,000 | $0.8800 | 56,818 | 148,025 | 19 May 2026 | Direct |
| Constantino Michael T. | HUMA | Common Stock | Purchase | 33.4% | $9,840 | $0.8945 | 11,000 | 43,950 | 18 May 2026 | Direct |
| Dale A. Sander | HUMA | Common Stock | Sale | -14.7% | $41,147 | $0.8967 | -45,887 | 267,213 | 18 May 2026 | Direct |
| Shamik J. Parikh | HUMA | Common Stock | Sale | -14.4% | $41,147 | $0.8967 | -45,887 | 272,713 | 18 May 2026 | Direct |
| Dale A. Sander | HUMA | Common Stock | Award | 15555% | 311,100 | 313,100 | 16 Nov 2025 | Direct | ||
| Shamik J. Parikh | HUMA | Common Stock | Award | 4148% | 311,100 | 318,600 | 16 Nov 2025 | Direct | ||
| Brady W. Dougan | HUMA | Stock Options (right to buy) | Award | 311,100 | 311,100 | 16 Nov 2025 | By spouse | |||
| Laura E. Niklason | HUMA | Stock Options (right to buy) | Award | 311,100 | 311,100 | 16 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.